|
|
|
Most Popular Stories
(Yahoo Finance)
|
Motorola Mobile Exec Reed Leaves |
SCHAUMBURG, Ill. (AP) -- Motorola Inc. said Friday that Stu Reed,
formerly president of its troubled mobile device business, has left the
company effective immediately.
A spokeswoman said Reed had been preparing for his departure after
Motorola announced last month that Chief Executive Greg Brown would
take direct control of the division, which saw sales and margins fall
last year.
Reed had led the division since last summer. The spokeswoman said she did not know Reed's plans.
Motorola shares soared last month when the company said it may sell the
mobile division, which accounted for $19 billion of Motorola's $36.6
billion in sales last year.
The company's cell-phone profit margin and sales slipped last year, and
the company fell to third place on the global cell-phone market behind
Nokia and Samsung Electronics Co.
Article provided by Jordan Robertson, AP Technology Writer
|
|
Justin Timberlake's 'Problem' With Women |
NEW YORK (AP) -- Justin Timberlake -- who isn't exactly hurting from
lack of attention from women -- is producing an NBC pilot about a
bachelor who strikes out with the ladies.
The Grammy-winning pop star is an executive producer on "My Problem
with Women," which follows thirtysomething Jose as he attempts to
understand his romantic failures through therapy sessions, Reveille
Studios announced Friday.
The show is based on "Mi Problema con las Mujeres," a Peruvian TV comedy.
Reveille, the production company headed by Ben Silverman before he
became NBC's entertainment chief last year, developed the BBC series
"The Office" for NBC and the Spanish-language telenova "Ugly Betty" for
ABC.
Article provided by Kevin Krolicki
|
|
Dangerous Cracks Appearing in Job Market |
WASHINGTON (AP) -- Dangerous cracks in the nation's job market are
deepening. Employers slashed jobs by the largest amount in five years
and hundreds of thousands of people dropped out of the labor force --
ominous signs that the country is falling toward a recession or has
already toppled into one.
For the second straight month, nervous employers got rid of jobs
nationwide. In February, they sliced payrolls by 63,000, even deeper
than the 22,000 cut in January, the Labor Department reported Friday.
The grim snapshot of the country's employment climate underscored the
heavy toll the housing and credit debacles are taking on companies,
jobseekers and the economy as a whole.
"It sounds like the recession bell is ringing for the U.S. economy,
although it is still faint," said Stuart Hoffman, chief economist at
PNC Financial Services Group.
Read More...
Article provided by Yahoo Finance
|
| |
Momenta Pharmaceuticals, Inc. ( MNTA ) Sets Priority on M-Enoxaparin Launch |
The US biotechnology industry includes about
1,000 companies, with combined annual revenue close to $50 billion. Rapid
advances in biotechnology marks the 2000s as the Biotechnology Era, with many
aspects of life revolutionized during this period. Momenta Pharmaceuticals,
Inc. (MNTA), a biotechnology company, specializes in the structural analysis of
complex mixture drugs. The Company applies its technology to the development of
generic versions of complex drug products, as well as to the discovery and
development of novel drugs.
The products of Momenta Pharmaceuticals include
M-Enoxaparin, a technology-enabled generic version of Lovenox that is used to
prevent and treat deep vein thrombosis and to support the treatment of acute
coronary syndromes; and M356, a technology-enabled generic version of Copaxone,
which is used for the reduction of the frequency of relapses in patients with
relapse-remitting multiple sclerosis.
Momenta Pharmaceuticals, Inc. recently reported
its financial results for the fourth quarter and year ended December 31, 2007.
For the fourth quarter of 2007, revenue was $10.0 million, compared to $4.0
million for the same period last year; while for the year ended December 31,
2007, revenue was $21.6 million, compared to $16.0 million for 2006. The
increase in revenue in both periods was a result of increased reimbursable
expenses associated with preparing for the potential commercial launch of
M-Enoxaparin in the U.S and amortization of the equity premium related to the
2006 collaboration agreement with Sandoz A.G. Read More..
Article provided by Jeff Bishop and the Beacon
Equity Research Team
|
Cereplast, Inc. ( CERP ) Supplies Quickpoint with Bioplastic Resin for Coffee Mugs |
|
The global plastics industry is estimated at 250
million tons and is growing 5% annually. According to BCC Research, the global
market for bio-plastics was 541 million pounds in 2007 (0.25 million tons) and
is expected to expand 17.3% annually and exceed 1.2 billion pounds (0.55
million tons) by 2012. Cereplast, Inc. (CERP), a bio-plastics manufacturing
company, designs and manufactures proprietary bio-based, sustainable plastics
which are used as substitutes for petroleum-based plastics in all major
converting processes – such as injection molding,
thermoforming, blow molding and extrusions – at a pricing
structure that is competitive with petroleum-based plastics. On the
cutting-edge of bio-based plastic material development, Cereplast now offers
resins to meet a variety of customer demands.
With the rapid evolution of bio-plastics
technology and rising bio-plastics demand, production and cost-efficiencies are
helping reduce bio-plastics prices to levels comparable to petroleum-based
plastics. Cereplast, Inc. positions itself strategically in the industry.
During the fourth quarter of 2006, the Company shifted its focus from selling
finished products made from bio-based resins to manufacturing and selling
bio-based resins. As of September 30, 2007, CERP and its converting partner had
successfully introduced a total of 57 bio-based products. Gross sales reached a
record $1.6 million in the first nine months of 2007, a 258% increase over the
comparable 2006 period.
Cereplast, Inc. recently announced that it is
supplying Quickpoint, a top manufacturer of promotional items, with bioplastic
resin for a new line of environmentally friendly coffee mugs. The different
mugs made from Cereplast resin are available in two forms –
a traditional coffee mug and commuter mug made to fit easily into car cup
holders.
Article provided by Jeff Bishop and the Beacon
Equity Research Team
| |
Taseko Mines Limited ( TGB ) Posted Net Earnings of $16.3 Million for Q4 2007 |
The United States, with a land area of over 9.6
million square kilometers, produces a wide variety of commodities from gold to
coal, and uses 25% of the world's energy reserves. It exports over $26 billion
worth of minerals and materials produced from minerals each year and considered
as the world's second largest producer of copper and gold. Taseko Mines Limited
(TGB) is a mining exploration, development and production company. Its main
assets are the Gibraltar copper-molybdenum mine, the Prosperity gold-copper
project and the Harmony gold prospect.
The mining industry is driven by increased
prices that can be attributed to the decline of the U.S. dollars and continued
strong demand for precious metals, in particular for gold jewelry. With this
market opportunity, metal producing companies are expected to increase
production to take advantage of the higher metal prices. Taseko's Prosperity
project hosts a large porphyry gold-copper project. Prior to 2001, the Company
had carried out extensive exploration, engineering, mine planning,
environmental and socio-economic studies on Prosperity, which hosts a large
porphyry copper-gold deposit amenable to large scale open pit mining. With
excellent metal prices currently and in the forecast, Taseko has re-initiated
work on the project.
Taseko's Gibraltar copper-molybdenum mine,
located in South Central British Columbia, is a 36,700-ton per day operation
with an annual life of mine average production of 70 million pounds of copper
and 1.1 million pounds of molybdenum. The mine is undergoing a major expansion
and modernization that will increase annual copper production capacity to 100
Million pounds by 2008. The mine life at the increased capacity is 16 years and
there are additional resources that could extend the mine life well over 20
years.
Article provided by Jeff Bishop and the Beacon Equity Research
Team
|
MiddleBrook Pharmaceuticals, Inc. ( MBRK ) Engages Morgan Stanley as Its Strategic Advisor |
|
The global pharmaceutical market is forecast to
grow to US$897 billion in 2011. According to IMS Health’s 2008 Global
Pharmaceutical Market and Therapy Forecast, the global pharmaceutical market is
expected to grow at a 5-6% pace in 2008, compared with 6-7% in 2007, with
global pharmaceutical sales forecast to expand to US$735 - 745 billion this
year. MiddleBrook Pharmaceuticals, Inc. (MBRK) is a company that engages in the
development and commercialization of anti-infective drug products for the
treatment of infectious diseases. It develops a proprietary, once-a-day
pulsatile delivery technology called PULSYS.
MiddleBrook Pharmaceuticals' pulsatile product
candidates include Amoxicillin PULSYS for adults and adolescents with
pharyngitis and/or tonsillitis; and Keflex PULSYS product candidate, based on
the antibiotic cephalexin, which is in Phase I clinical trials for skin and
skin structure infections. In addition, MiddleBrook Pharmaceuticals sells its
Keflex products in both capsule and powder formulations for the treatment of
skin and skin structure infections, and upper respiratory tract infections
primarily through pharmaceutical distributors and wholesalers to physicians,
hospitals, and pharmacies in the United States.
To strengthen the Company's sales, MiddleBrook
Pharmaceuticals has a collaboration agreement with Par Pharmaceutical for the
distribution and marketing of the Company's generic formulation of Abbott's
Biaxin XL (extended release clarithromycin).
Article provided by Jeff Bishop and the Beacon
Equity Research Team
| |
|
|
